Singular Research reiterated its BioSante Pharmaceuticals (NASDAQ:

) Buy rating and maintained its $7 price target in a research report published today. In the report, Singular Research states, "The Phase III clinical trials for LibiGel® are completed and the company is compiling the data. Management has announced it will release a data summary in December 2011." Shares of BioSante Pharmaceuticals were trading at $2.58 at the time of posting, up 1.57% from Monday's market close.